Latest & greatest articles for doxycycline

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on doxycycline or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on doxycycline and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for doxycycline

21. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. (Full text)

Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Doxycycline inhibits formation and progression of abdominal aortic aneurysms (AAAs) in preclinical models of the disease, but it is unclear whether and how this observation translates to humans.To test whether doxycycline inhibits AAA progression in humans.Randomized, placebo-controlled, double-blind trial. (Dutch Trial Registry: NTR 1345) SETTING: 14 Dutch hospitals.286 patients with small AAAs between October (...) 2008 and June 2011.Daily dose of 100 mg of doxycycline (n = 144) or placebo (n = 142) for 18 months.The primary outcome measure was aneurysm growth at 18 months, as estimated by repeated single-observer ultrasonography. Secondary outcomes included growth at 6 and 12 months and the need for elective surgery.Mean aneurysm diameter (approximately 43 mm) and other baseline characteristics were similar in both groups. Doxycycline treatment was associated with increased aneurysm growth (4.1 mm

2013 Annals of Internal Medicine Controlled trial quality: predicted high PubMed abstract

22. Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. (Full text)

Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial. Melioidosis, an infectious disease caused by the Gram-negative bacillus Burkholderia pseudomallei, is difficult to cure. Antimicrobial treatment comprises intravenous drugs for at least 10 days, followed by oral drugs for at least 12 weeks. The standard oral regimen based on trial (...) evidence is trimethoprim-sulfamethoxaxole (TMP-SMX) plus doxycycline. This regimen is used in Thailand but is associated with side-effects and poor adherence by patients, and TMP-SMX alone is recommended in Australia. We compared the efficacy and side-effects of TMP-SMX with TMP-SMX plus doxycycline for the oral phase of melioidosis treatment.For this multi-centre, double-blind, non-inferiority, randomised placebo-controlled trial, we enrolled patients (aged ≥15 years) from five centres in northeast

2013 Lancet Controlled trial quality: predicted high PubMed abstract

23. Doxycycline monohydrate - Rosacea treatment

Doxycycline monohydrate - Rosacea treatment Common Drug Review CDEC Meeting — January 16, 2013; CDEC Reconsideration — March 20, 2013 Notice of CDEC Final Recommendation — March 27, 2013 Page 1 of 4 © 2013 CADTH FINAL CDEC RECOMMENDATION DOXYCYCLINE MONOHYDRATE (Apprilon – Galderma Canada Inc.) Indication: Inflammatory Rosacea Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that 40 mg doxycycline modified- release capsules not be listed. Reason for the Recommendation (...) : The Committee considered the comparative clinical benefit of 40 mg doxycycline modified- release (MR) capsules to be uncertain due to limitations in the design and analysis of the single randomized controlled trial (RCT) (ROSE-401) that compared 40 mg doxycycline MR capsules with 100 mg doxycycline immediate-release (IR) capsules. Background: Doxycycline monohydrate has a Health Canada indication for the treatment of inflammatory lesions (papules and pustules) of rosacea in adult patients. Doxycycline has

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

24. Azithromycin versus doxycycline for genital chlamydia infections - a meta-analysis of randomised controlled trials

Azithromycin versus doxycycline for genital chlamydia infections - a meta-analysis of randomised controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2013 PROSPERO

25. Ciprofloxacin or Doxycycline for the Treatment of Anthrax: A Review of the Clinical and Cost-Effectiveness

Ciprofloxacin or Doxycycline for the Treatment of Anthrax: A Review of the Clinical and Cost-Effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within (...) is given to CADTH. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Ciprofloxacin or Doxycycline for the Treatment of Anthrax: A Review of the Clinical and Cost-Effectiveness DATE: 27 November 2012 CONTEXT AND POLICY ISSUES The potential use of anthrax as a biological terrorist attack has

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

26. Doxycycline ineffective for osteoarthritis of the knee or hip

Doxycycline ineffective for osteoarthritis of the knee or hip PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Doxycycline ineffective for osteoarthritis of the knee or hip Clinical question How effective is doxycycline for osteoarthritis (OA) of the knee or hip? Bottom line Compared to placebo, there is minimal or no symptomatic benefit (pain reduction and improved physical function (...) ) with doxycycline treatment. The small benefit observed in joint space narrowing is of questionable clinical relevance and outweighed by safety issues. Doxycycline should therefore not be recommended for the treatment of osteoarthritis of the knee or hip. Caveat The trial was designed to detect differences in joint space narrowing rather than differences in clinical outcomes. No threshold for the level of knee pain was used for inclusion and the average level of knee pain was low at baseline, leaving little

2011 Cochrane PEARLS

27. Subantimicrobial-Dose Doxycycline (SDD) Periodontal therapy reduces serum biomarkers of systemic inflammation and can increase high-density lipoprotein

Subantimicrobial-Dose Doxycycline (SDD) Periodontal therapy reduces serum biomarkers of systemic inflammation and can increase high-density lipoprotein UTCAT856, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Subantimicrobial-Dose Doxycycline (SDD) Periodontal Therapy Reduces Serum Biomarkers Of Systemic Inflammation And Can Increase High-Density Lipoprotein Clinical Question In post-menopausal women with chronic (...) periodontitis does a systemic dose of Doxycycline in comparison to placebo increase high-density lipoprotein (HDL) levels? Clinical Bottom Line In post-menopausal women with chronic periodontitis Subantimicrobial-Dose Doxycycline Periodontal therapy reduces serum biomarkers of systemic inflammation and among women more than five years post-menopausal, the SDD regimen elevated their level of high-density lipoprotein (HDL) cholesterol. (See Comments on the CAT below) Best Evidence (you may view more info

2011 UTHSCSA Dental School CAT Library

28. Systematic review: Low-quality evidence that atovaquone-proguanil and doxycycline are better tolerated prophylactic antimalarial regimens in travellers than mefloquine

Systematic review: Low-quality evidence that atovaquone-proguanil and doxycycline are better tolerated prophylactic antimalarial regimens in travellers than mefloquine Low-quality evidence that atovaquone-proguanil and doxycycline are better tolerated prophylactic antimalarial regimens in travellers than mefloquine | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-quality evidence that atovaquone-proguanil and doxycycline are better

2010 Evidence-Based Nursing

29. A randomized trial of doxycycline for Mansonella perstans infection. (Full text)

A randomized trial of doxycycline for Mansonella perstans infection. Mansonella perstans infection is common in areas of Africa where Wuchereria bancrofti, a causative agent of lymphatic filariasis, is endemic. M. perstans is refractory to standard antifilarial therapies. The recent discovery of bacterial endosymbionts (e.g., wolbachia) in most filarial species, including M. perstans, provides new therapeutic options for reducing microfilaremia.In an open-label, randomized trial, we recruited (...) subjects with M. perstans microfilaremia, with or without concomitant W. bancrofti infection, from four villages in Mali and randomly assigned them to receive doxycycline, at a dose of 200 mg daily for 6 weeks (106 subjects), or no treatment (110). At 6 months, subjects who were coinfected with W. bancrofti underwent a second random assignment, to treatment with a single dose of albendazole (400 mg) and ivermectin (150 microg per kilogram of body weight) or no treatment. Subjects were monitored daily

2009 NEJM Controlled trial quality: uncertain PubMed abstract

30. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial (Abstract)

Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial Use of intravenous penicillin and ceftriaxone to treat Lyme neuroborreliosis is well documented, although oral doxycycline could be a cost-effective alternative. We aimed to compare the efficacy of oral doxycycline with intravenous ceftriaxone for the treatment of Lyme neuroborreliosis.From April, 2004, to October, 2007, we recruited consecutive (...) adult patients from nine hospitals in southern Norway into a non-inferiority trial. Inclusion criteria were neurological symptoms suggestive of Lyme neuroborreliosis without other obvious causes, and presence of any of the following: a CSF white-cell count of more than five per mL; intrathecal production of specific Borrelia burgdorferi antibodies; or acrodermatitis chronicum atrophicans. Patients were randomly allocated to receive 200 mg oral doxycycline or 2 g intravenous ceftriaxone once per day

2008 EvidenceUpdates Controlled trial quality: predicted high

31. Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever. (Abstract)

Postexposure treatment with doxycycline for the prevention of tick-borne relapsing fever. Tick-borne relapsing fever (TBRF) is an acute febrile illness. In Israel, TBRF is caused by Borrelia persica and is transmitted by Ornithodoros tholozani ticks. We examined the safety and efficacy of postexposure treatment to prevent TBRF.In a double-blind, placebo-controlled trial, 93 healthy subjects with suspected tick exposure (52 with signs of tick bites and 41 close contacts--those without signs (...) but with a similar risk of contact with ticks) were randomly assigned to receive either doxycycline (Dexxon, in a dose of 200 mg the first day and then 100 mg per day for four days) or placebo after presumed exposure to TBRF. Cases of TBRF were defined by fever and a positive blood smear. Serologic analysis for cross-reactivity to Borrelia burgdorferi and polymerase chain reaction (PCR) for the borrelia glpQ gene were also performed.After randomization, 47 subjects (26 with signs of tick bites and 21 close

2006 NEJM Controlled trial quality: predicted high

32. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. (Abstract)

Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Wolbachia endosymbionts of filarial nematodes are vital for larval development and adult-worm fertility and viability. This essential dependency on the bacterium for survival of the parasites has provided a new approach to treat filariasis with antibiotics. We used this strategy to investigate the effects of doxycycline treatment on the major cause of lymphatic (...) filariasis, Wuchereria bancrofti.We undertook a double-blind, randomised, placebo-controlled field trial of doxycycline (200 mg per day) for 8 weeks in 72 individuals infected with W bancrofti from Kimang'a village, Pangani, Tanzania. Participants were randomly assigned by block randomisation to receive capsules of doxycycline (n=34) or placebo (n=38). We assessed treatment efficacy by monitoring microfilaraemia, antigenaemia, and ultrasound detection of adult worms. Follow-up assessments were done at 5

2005 Lancet Controlled trial quality: predicted high

33. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials

Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials Lau C Y, Qureshi A K Authors' objectives To evaluate the efficacy and tolerance of azithromycin versus doxycycline for genital chlamydial infection. Searching (...) Studies published in English were retrieved from the following databases: MEDLINE and Pre-MEDLINE (from 1975 to August 2001), HealthSTAR (from 1975 to August 2001), EBM Reviews: Best Evidence (from September 1991 to January/February 2001), EBM Reviews: Cochrane Database of Systematic Reviews (second quarter of 2001), and EBM Reviews: DARE (second quarter of 2001). The medical subject headings 'CT' and 'doxycycline' or 'CT' and 'azithromycin' were used as search terms. Bibliographies of computer

2002 DARE.

34. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. (Abstract)

Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. It is unclear whether antimicrobial treatment after an Ixodes scapularis tick bite will prevent Lyme disease.In an area of New York where Lyme disease is hyperendemic we conducted a randomized, double-blind, placebo-controlled trial of treatment with a single 200-mg dose of doxycycline in 482 subjects who had removed attached I. scapularis ticks from their bodies within the previous (...) 72 hours. At base line, three weeks, and six weeks, subjects were interviewed and examined, and serum antibody tests were performed, along with blood cultures for Borrelia burgdorferi. Entomologists confirmed the species of the ticks and classified them according to sex, stage, and degree of engorgement.Erythema migrans developed at the site of the tick bite in a significantly smaller proportion of the subjects in the doxycycline group than of those in the placebo group (1 of 235 subjects [0.4

2001 NEJM Controlled trial quality: predicted high

35. Doxycycline and rifampicin for mild scrub-typhus infections in northern Thailand: a randomised trial. (Abstract)

Doxycycline and rifampicin for mild scrub-typhus infections in northern Thailand: a randomised trial. Some strains of scrub typhus in northern Thailand are poorly responsive to standard antirickettsial drugs. We therefore did a masked, randomised trial to compare rifampicin with standard doxycycline therapy for patients with scrub typhus.Adult patients with strictly defined, mild scrub typhus were initially randomly assigned 1 week of daily oral treatment with 200 mg doxycycline (n=40), 600 mg (...) rifampicin (n=38), or doxycycline with rifampicin (n=11). During the first year of treatment, the combined regimen was withdrawn because of lack of efficacy and the regimen was replaced with 900 mg rifampicin (n=37). Treatment outcome was assessed by fever clearance time (the time for oral temperature to fall below 37.3 degrees C).About 12,800 fever patients were screened during the 3-year study to recruit 126 patients with confirmed scrub typhus and no other infection, of whom 86 completed therapy

2000 Lancet Controlled trial quality: uncertain

36. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia

Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia Ailani R K, Agastya G, Ailani R K, Mukunda B N, Shekar R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Doxycycline for hospitalised patients with community-acquired pneumonia. The dosage was 100mg given intravenously every 12 hours. This was switched to 100mg orally every 12 hours for patients in the intervention group who improved. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study

1999 NHS Economic Evaluation Database.

37. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. (Abstract)

Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. Localized Lyme disease, manifested by erythema migrans, is usually treated with oral doxycycline or amoxicillin. Whether acute disseminated Borrelia burgdorferi infection should be treated differently from localized infection is unknown.We conducted a prospective, open-label, randomized, multicenter study comparing parenteral ceftriaxone (2 g once daily for 14 days) with oral doxycycline (100 mg twice (...) with ceftriaxone (85 percent) and those treated with doxycycline (88 percent); treatment was considered to have failed in only one patient in each group. Among patients whose infections were cured, 18 of 67 patients in the ceftriaxone group (27 percent) reported one or more residual symptoms at the last follow-up visit, as did 10 of 71 patients in the doxycycline group (14 percent, P > or = 0.05). Mild arthralgia was the most common persistent symptom. Both regimens were well tolerated; only four patients (6

1997 NEJM Controlled trial quality: uncertain

38. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis

Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis Magid D, Douglas J, Schwartz S Record Status (...) . Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Annals of Internal Medicine 1996; 124(4): 389-399 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Analysis of Variance; Azithromycin /administration & Chlamydia Infections /drug therapy /economics; Chlamydia trachomatis; Cost-Benefit Analysis; Decision Trees; Doxycycline /administration & Drug Administration Schedule; Female; Genital Diseases

1996 NHS Economic Evaluation Database.

39. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. (Abstract)

Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae 01 or 0139. Effective antimicrobial therapy can reduce the duration and volume of cholera diarrhoea by half. However, such treatment is currently limited by Vibrio cholerae resistance to the drugs commonly prescribed for cholera, and by the difficulties involved in the administration of multi-drug doses under field conditions. Because of its favourable pharmacokinetics we thought (...) it likely that single-dose ciprofloxacin would be effective in the treatment of cholera.In this double-blind study treatment was either a single 1 g oral dose of ciprofloxacin plus doxycycline placebo, or a single 300 mg oral dose of doxycycline plus ciprofloxacine placebo. 130 moderately or severely dehydrated men infected with V cholerae 01 and 130 infected with V cholerae 0139 were randomly assigned treatment. Patients stayed in hospital for 5 days. We measured fluid intake and stool volume every 6 h

1996 Lancet Controlled trial quality: predicted high

40. Randomised double blind trial of single dose doxycycline for treating cholera in adults. (Full text)

Randomised double blind trial of single dose doxycycline for treating cholera in adults. To compare the efficacy of a single dose of doxycycline (200 or 300 mg) with the standard multiple doses of tetracycline in patients with cholera.Randomised double blind controlled trial. Patients were given a single 200 mg dose of doxycycline, a single 300 mg dose of doxycycline, or multiple doses of tetracycline (500 mg, six hourly intervals).Hospital in Bangladesh treating diarrhoea.261 Patients aged (...) weight) and till diarrhoea stopped (296 ml/kg body weight) were significantly higher in patients receiving 200 mg doxycycline as a single dose than in patients receiving either standard tetracycline (242 ml/kg body weight and 254 ml/kg body weight) or 300 mg doxycycline (226 ml/kg body weight and 255 ml/kg body weight). Similarly, median consumption of oral rehydration solution (18.45 l) was significantly higher in patients receiving 200 mg doxycycline than in patients receiving either 300 mg

1990 BMJ Controlled trial quality: predicted high PubMed abstract